I agree that this site is using cookies. You can find further informations here.
X
Pavlakis, N.
690  results:
Search for persons X
?
1

Single-centre experience with peptide receptor radionuclide..:

Gordon, S. ; Chan, D. L. H. ; Bernard, E. J....
Journal of Cancer Research and Clinical Oncology.  149 (2023)  10 - p. 7717-7728 , 2023
Link: https://doi.org/10.1007/..
 
?
2

OA04.03 Australian Registry and Biobank of Thoracic Cancers..:

Rogers, J. ; Itchins, M. ; Harden, S....
Journal of Thoracic Oncology.  18 (2023)  11 - p. S51-S52 , 2023
Link: https://doi.org/10.1016/..
 
?
3

P2.11-05 SHERLOCK: Phase II Trial of Upfront Sotorasib with..:

Lee, C. ; Pavlakis, N. ; Zhou, D.D.-X....
Journal of Thoracic Oncology.  18 (2023)  11 - p. S361-S362 , 2023
Link: https://doi.org/10.1016/..
 
?
4

P2.10-01 ALKTERNATE: A Pilot Study Alternating Lorlatinib w..:

Itchins, M. ; Liang, S. ; Brown, C....
Journal of Thoracic Oncology.  18 (2023)  11 - p. S351-S352 , 2023
Link: https://doi.org/10.1016/..
 
?
5

MA17.05 Real World Outcomes of Immunotherapy (IO) for Pleur..:

McNamee, N. ; Harvey, C. ; Gray, L....
Journal of Thoracic Oncology.  18 (2023)  11 - p. S163 , 2023
Link: https://doi.org/10.1016/..
 
?
6

60 CONTACT-01: Efficacy and safety from a phase III study o..:

Neal, J. ; Pavlakis, N. ; Kim, S-W....
Journal of Thoracic Oncology.  18 (2023)  4 - p. S39-S40 , 2023
Link: https://doi.org/10.1016/..
 
?
7

P1.11-02 DYNAMALK: Dynamic ctDNA Profiling in ALK+ NSCLC. A..:

Itchins, M. ; Abualhial, F. ; Rogers, J....
Journal of Thoracic Oncology.  18 (2023)  11 - p. S204-S205 , 2023
Link: https://doi.org/10.1016/..
 
?
8

EP16.03-005 Australian Non-Small Cell Lung Cancer (NSCLC) B..:

Gard, G. ; Kao, S. ; Solomon, B....
Journal of Thoracic Oncology.  17 (2022)  9 - p. S587 , 2022
Link: https://doi.org/10.1016/..
 
?
9

Cost of treating metastatic colorectal cancer: a systematic..:

Bhimani, N. ; Wong, G.Y.M. ; Molloy, C....
Public Health.  211 (2022)  - p. 97-104 , 2022
Link: https://doi.org/10.1016/..
 
?
10

EP08.02-109 A Drug-Drug Interaction Study of Mobocertinib a..:

Hanley, M.J. ; Zhang, S. ; Pavlakis, N....
Journal of Thoracic Oncology.  17 (2022)  9 - p. S453-S454 , 2022
Link: https://doi.org/10.1016/..
 
?
11

Defining the rate of nutritional and metabolic derangements..:

Percy, K.L. ; Ooi, Y.X. ; Nahm, C.B....
Pancreatology.  22 (2022)  7 - p. 1028-1034 , 2022
Link: https://doi.org/10.1016/..
 
?
12

EP04.01-023 Development of an Australia and New Zealand Lun..:

Stirling, R. ; Smith, S. ; Brand, M....
Journal of Thoracic Oncology.  17 (2022)  9 - p. S256-S257 , 2022
Link: https://doi.org/10.1016/..
 
?
13

DREAM3R: DuRvalumab With chEmotherapy as First Line treAtme..:

Forde, P. ; Kindler, H. ; Zauderer, M....
International Journal of Radiation Oncology*Biology*Physics.  112 (2022)  2 - p. e9-e10 , 2022
Link: https://doi.org/10.1016/..
 
?
14

A Randomized Phase 2 Trial of Nivolumab and Stereotactic Ab..:

Mitchell, P. ; O'Byrne, K.J. ; Brown, C....
International Journal of Radiation Oncology*Biology*Physics.  111 (2021)  3 - p. S10-S11 , 2021
Link: https://doi.org/10.1016/..
 
?
15

Impact of COVID-19 on cancer service delivery: a follow-up ..:

Chazan, G. ; Franchini, F. ; Alexander, M....
ESMO Open.  6 (2021)  5 - p. 100224 , 2021
Link: https://doi.org/10.1016/..
 
1-15